1naresh
Array ( [urn:ac.highwire.org:guest:identity] => Array ( [runtime-id] => urn:ac.highwire.org:guest:identity [type] => guest [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [urn:ac.highwire.org:guest:privilege] => Array ( [runtime-id] => urn:ac.highwire.org:guest:privilege [type] => privilege-set [privilege-set] => GUEST ) ) [credentials] => Array ( [method] => guest ) ) ) 1nareshArray ( [urn:ac.highwire.org:guest:identity] => Array ( [runtime-id] => urn:ac.highwire.org:guest:identity [type] => guest [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [urn:ac.highwire.org:guest:privilege] => Array ( [runtime-id] => urn:ac.highwire.org:guest:privilege [type] => privilege-set [privilege-set] => GUEST ) ) [credentials] => Array ( [method] => guest ) ) )Table 3:Radiologic follow-up results
Overall Aspirin+Clopidogrel Group Aspirin+Ticagrelor Group P Value Follow-up (%) 211/233 (90.6) 126/140 (90.0) 85/93 (91.4) Period (median) (IQR) (mo) 25.1 37.0 (25.0–48.75) 13.8 (7.5–23.1) <.001 Aneurysm occlusiona (%) .552 I 154 (73.0) 92 (73.0) 62 (72.9) II 27 (12.8) 14 (11.1) 13 (15.3) III 30 (14.2) 20 (15.9) 10 (11.8) In-stent stenosis .603 <50% 188 (89.1) 114 (90.5) 74 (87.1) >50% 6 (2.8) 2 (1.6) 4 (4.7) Unknownb 17 (8.1) 10 (7.9) 7 (8.2) Retreatment 16 (6.8) 10 (7.0) 6 (6.5) >.999